Producer
Orchid Pharma Limited
Indian cephalosporin and penicillin API manufacturer (NSE: ORCHPHARMA, HQ Chennai Tamil Nadu; restructured through insolvency 2019, acquired by Dhanuka Laboratories); one of India's largest sterile cephalosporin API producers, operating dedicated injectable-grade cephalosporin facilities in Chennai. Orchid Pharma went through a prolonged financial restructuring (defaulted on debt 2012; insolvency resolution process 2018-2019) before being acquired by Dhanuka Group. Despite financial distress, Orchid's cephalosporin manufacturing expertise — including sterile 7-ACA processing and downstream injectable cephalosporin production — was preserved. Orchid is one of the few non-Chinese sterile cephalosporin API manufacturers globally.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Orchid Pharma Limited supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Orchid Pharma Limited makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Sterile Cephalosporin APIs
70%Oral Cephalosporin APIs
20%Penicillin APIs
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2024
Orchid Pharma is one of the very few non-Chinese manufacturers of sterile injectable-grade cephalosporin APIs in the world — a category that, outside China, has essentially been eliminated by pricing competition. Sterile cephalosporins (ceftriaxone, cefuroxime, cefazolin) are injected directly into hospital patients in ICUs, surgical wards, and emergency departments; their sterility requires manufacturing facilities certified to the highest GMP standards. Following its 2019 acquisition by Dhanuka Laboratories and financial restructuring, Orchid represents the last significant non-Chinese sterile cephalosporin API manufacturer with validated FDA-approved capacity outside China. For hospital systems and pharmaceutical companies seeking supply chain diversification from Chinese antibiotic APIs after COVID-19 exposed concentration risks, Orchid is one of the very few viable alternatives — and its near-bankruptcy demonstrated how difficult it is to sustain non-Chinese sterile antibiotic API manufacturing economically.
Orchid Pharma Limited ↗Origin2023
Orchid Chemicals & Pharmaceuticals (renamed Orchid Pharma after restructuring) was founded in Chennai in 1992 by K. Raghavendra Rao — an Indian pharmaceutical entrepreneur who identified the cephalosporin API market as underserved by Indian manufacturers, most of whom focused on penicillin-based APIs. Orchid built dedicated sterile cephalosporin manufacturing capacity at its Alathur facility near Chennai, achieving US FDA and European regulatory approvals that are exceptionally difficult to obtain for sterile antibiotic manufacturing. The company's financial distress (debt default 2012, insolvency proceedings 2018-2019) was caused substantially by the collapse of global cephalosporin API prices as Chinese producers (CSPC, NCPC, Lupin precursors) expanded capacity dramatically and priced at levels Indian manufacturers could not profitably meet. Orchid's insolvency demonstrates how Chinese antibiotic API pricing power eliminated the Indian cephalosporin API industry that once existed outside China.
Orchid Pharma Limited ↗